Endocrinology · Diabetes Mellitus
The facts most likely to be tested
Type 1 Diabetes Mellitus results from autoimmune destruction of pancreatic beta cells in the islets of Langerhans, leading to absolute insulin deficiency.
Patients typically present with the classic triad of polyuria, polydipsia, and polyphagia, often accompanied by unexplained weight loss.
The most common initial presentation in children is Diabetic Ketoacidosis (DKA), characterized by hyperglycemia, anion gap metabolic acidosis, and ketonemia.
Diagnostic criteria include a random plasma glucose ≥ 200 mg/dL with classic symptoms or a fasting plasma glucose ≥ 126 mg/dL on two separate occasions.
Laboratory findings in DKA reveal low serum bicarbonate, elevated beta-hydroxybutyrate, and a positive urine nitroprusside test for ketones.
The presence of glutamic acid decarboxylase (GAD65) antibodies or islet cell cytoplasmic antibodies confirms the autoimmune etiology of the disease.
First-line management requires basal-bolus insulin therapy to mimic physiological secretion and prevent long-term microvascular complications like retinopathy and nephropathy.
Vignette unlocked
A 12-year-old male is brought to the emergency department by his parents due to a 3-day history of polyuria, polydipsia, and lethargy. Physical examination reveals dry mucous membranes, tachycardia, and deep, rapid respirations. Laboratory studies show a blood glucose of 450 mg/dL, a pH of 7.15, and a serum bicarbonate of 12 mEq/L. A urine dipstick is positive for ketones.
What is the most appropriate initial management for this patient?
Intravenous fluid resuscitation and continuous insulin infusion
The patient is presenting with DKA, a life-threatening complication of Type 1 Diabetes Mellitus; the immediate priority is fluid resuscitation to restore perfusion and insulin therapy to suppress ketogenesis.
Full handout
High yield triage
Etiology / Epidemiology
Autoimmune pancreatic beta-cell destruction in genetically susceptible individuals, often triggered by environmental factors.
Clinical Manifestations
Classic triad of polyuria, polydipsia, and weight loss; Kussmaul breathing indicates diabetic ketoacidosis.
Diagnosis
Fasting plasma glucose ≥ 126 mg/dL or HbA1c ≥ 6.5% on two separate occasions.
Treatment
Lifelong insulin therapy; do not delay insulin in the setting of hyperglycemia and ketosis.
Prognosis
Risk of microvascular complications (retinopathy, nephropathy, neuropathy) reduced by strict glycemic control.
Full handout
Epidemiology & Etiology
Typically presents in childhood or adolescence due to T-cell mediated autoimmune destruction of pancreatic beta cells. Strong association with HLA-DR3 and HLA-DR4 genotypes. Environmental triggers, such as viral infections, may precipitate clinical onset in predisposed patients.
Pertinent Anatomy
The islets of Langerhans in the pancreas are the primary site of pathology. Destruction of beta cells leads to an absolute insulin deficiency, preventing glucose uptake in peripheral tissues.
Pathophysiology
Absolute insulin deficiency leads to unchecked gluconeogenesis and glycogenolysis. Without insulin, cells cannot utilize glucose, resulting in starvation-state metabolism and lipolysis. This releases free fatty acids, which are converted into ketones, leading to the metabolic acidosis of diabetic ketoacidosis.
Clinical Manifestations
Patients present with rapid onset of polyuria, polydipsia, polyphagia, and unexplained weight loss. Diabetic ketoacidosis is often the initial presentation, characterized by Kussmaul breathing, fruity breath odor, and abdominal pain. Altered mental status and dehydration are critical red flags requiring immediate stabilization.
Diagnosis
The gold standard for diagnosis is a fasting plasma glucose ≥ 126 mg/dL or a random plasma glucose ≥ 200 mg/dL with classic symptoms. An HbA1c ≥ 6.5% is also diagnostic. Presence of islet cell antibodies or glutamic acid decarboxylase (GAD) antibodies confirms the autoimmune etiology.
Treatment
Management requires lifelong basal-bolus insulin regimens. Never withhold insulin in patients with ketosis. Patients must perform frequent blood glucose monitoring and carbohydrate counting. Hypoglycemia is the most common acute adverse effect of therapy.
Prognosis
Long-term outcomes depend on maintaining HbA1c < 7.0% to prevent microvascular complications. Annual screening for diabetic nephropathy (via urine albumin-to-creatinine ratio) and diabetic retinopathy (via dilated eye exam) is mandatory.
Differential Diagnosis
Type 2 Diabetes: usually associated with obesity and insulin resistance
MODY: autosomal dominant inheritance with onset before age 25
LADA: latent autoimmune diabetes in adults with slower progression
Diabetes Insipidus: polyuria without hyperglycemia
Psychogenic Polydipsia: normal serum glucose levels